Here, we found that targeting BRD4 is one of the most promising methods to boost anti‐tumour immunity in combination with radiation and cisplatin as well as concurrent chemoradiotherapy via prohibiting the treatment‐induced PD‐L1 up‐regulation. This evidence concerns the gene BRD4 and neoplasm.